- Home
- REFI vs SGHT Comparison
REFI vs SGHT Comparison
Compare REFI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | SGHT |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 193.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REFI | SGHT |
|---|---|---|
| Price | $13.13 | $8.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $20.00 | $7.66 |
| AVG Volume (30 Days) | 119.8K | ★ 245.0K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 15.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | $54,287,847.00 | ★ $76,052,000.00 |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $4.07 | $12.07 |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.85 | $2.03 |
| 52 Week High | $16.29 | $9.24 |
Technical Indicators
Market Signals| Indicator | REFI | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 66.50 |
| Support Level | $12.76 | $8.21 |
| Resistance Level | $13.25 | $9.21 |
| Average True Range (ATR) | 0.28 | 0.50 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 56.18 | 79.26 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.